Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 4, 2011, Pages 237-248

  Williams, Chadwick ^a   Panaccione, Remo ^b   Ghosh, Subrata ^c   Rioux, Kevin ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

5 aminosalicylic acid; Crohn's disease; Delayed action preparations; Inflammatory bowel disease; Mesalazine; Ulcerative colitis

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE;

CHEMOPROPHYLAXIS; COLON CANCER; CROHN DISEASE; DELAYED DRUG RELEASE; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG SAFETY; ENTERITIS; HUMAN; MAINTENANCE THERAPY; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SMALL INTESTINE; ULCERATIVE COLITIS;

EID: 79959561435     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11405250     Document Type: Review

References (56)

1. Akobeng A.K. Gardener E. (2005) Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 1: CD003715–CD003715.
2. Allgayer H. (1992) Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am 21: 643–658.
3. Asano T.K. McLeod R.S. (2004) Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum 47: 665–673.
4. Baert F. Moortgat L. van Assche G. Caenepeel P. Vergauwe P. de Vos M. et al (2010) Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138: 463–468. quiz e410-e461.
5. Bernstein C.N. Blanchard J.F. Kliewer E. Wajda A. (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854–862.
6. Biddle W.L. Miner P.B. Jr (1990) Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 99: 113–118.
7. Caprilli R. Andreoli A. Capurso L. Corrao G. D'Albasio G. Gioieni A. et al (1994) Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Therapeut 8: 35–43.
8. Chan E.P. Lichtenstein G.R. (2006) Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 35: 675–712.
9. Desreumaux P. Ghosh S. (2006) Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther 24(Suppl. 1): 2–9.
10. Dignass A. Bokemeyer B. Adamek H. Mross M. Vinter-Jensen L. Börner N. et al (2009) Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 7 (7): 762–769.
11. Doherty G. Bennett G. Patil S. Cheifetz A. Moss A.C. (2009) Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 4: CD006873–CD006873.
12. Eaden J. Abrams K. Ekbom A. Jackson E. Mayberry J. (2000) Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Therapeut 14: 145–153.
13. Ford A.C. Khan K.J. Talley N.J. Moayyedi P. (2011) 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 106 (3): 413–420.
14. Froslie K.F. Jahnsen J. Moum B.A. Vatn M.H. (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133: 412–422.
15. Gearry R.B. Ajlouni Y. Nandurkar S. Iser J.H. Gibson P.R. (2007) 5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists. Inflamm Bowel Dis 13: 1009–1015.
16. Hanauer S.B. (1996) Inflammatory bowel disease. N Engl J Med 334: 841–848.
17. Hanauer S.B. Sandborn W.J. Dallaire C. Archambault A. Yacyshyn B. Yeh C. et al (2007) Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 21: 827–834.
18. Hanauer S.B. Sandborn W.J. Kornbluth A. Katz S. Safdi M. Woogen S. et al (2005) Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 100: 2478–2485.
19. Hanauer S.B. Sninsky C.A. Robinson M. Powers B.J. McHattie J.D. Mayle J. et al (1996) An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med 124: 204–211.
20. Hanauer S.B. Stromberg U. (2004) Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2: 379–388.
21. Iacucci M. de Silva S. Ghosh S. (2010) Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol 24: 127–133.
22. Jiang C. Ting A.T. Seed B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82–86.
23. Kamm M.A. Lichtenstein G.R. Sandborn W. Schreiber S. Lees K. Barrett K. et al (2009) Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis. Inflamm Bowel Dis 15: 1–8.
24. Kamm M.A. Lichtenstein G.R. Sandborn W.J. Schreiber S. Lees K. Barrett K. et al (2008) Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57: 893–902.
25. Kamm M.A. Sandborn W.J. Gassull M. Schreiber S. Jackowski L. Butler T. et al (2007) Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132: 66–75. quiz 432–433.
26. Kane S. Huo D. Aikens J. Hanauer S. (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114: 39–43.
27. Keohane J. O'Mahony C. O'Mahony L. O'Mahony S. Quigley E.M. Shanahan F. (2011) Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterology 1–6.
28. Kruis W. Bar-Meir S. Feher J. Mickisch O. Mlitz H. Faszczyk M. et al (2003) The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 1: 36–43.
29. Kruis W. Kiudelis G. Racz I. Gorelov I.A. Pokrotnieks J. Horynski M. et al (2009) Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 58: 233–240.
30. Langholz E. Munkholm P. Nielsen O.H. Kreiner S. Binder V. (1991) Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 26: 1247–1256.
31. Lichtenstein G.R. Kamm M.A. Boddu P. Gubergrits N. Lyne A. Butler T. et al (2007) Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 5: 95–102.
32. Lichtenstein G.R. Rutgeerts P. (2010) Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 16: 338–346.
33. Mahida Y.R. Jewell D.P. (1990) Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 45: 88–92.
34. Marteau P. Probert C.S. Lindgren S. Gassul M. Tan T.G. Dignass A. et al (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54: 960–965.
35. Moody G.A. Jayanthi V. Probert C.S. MacKay H. Mayberry J.F. (1996) Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 8: 1179–1183.
36. Patel H. Barr A. Jeejeebhoy K.N. (2009) Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 23: 170–176.
37. Prantera C. Kohn A. Campieri M. Caprilli R. Cottone M. Pallone F. et al (2009) Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX ®with Asacol ®. Aliment Pharmacol Therapeut 30: 908–918.
38. Prantera C. Viscido A. Biancone L. Francavilla A. Giglio L. Campieri M. (2005) A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 11: 421–427.
39. Rasmussen S.N. Lauritsen K. Tage-Jensen U. Nielsen O.H. Bytzer P. Jacobsen O. et al (1987) 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 22: 877–883.
40. Reinisch W. Angelberger S. Petritsch W. Shonova O. Lukas M. Bar-Meir S. et al (2010) Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 59: 752–759.
41. Rousseaux C. Lefebvre B. Dubuquoy L. Lefebvre P. Romano O. Auwerx J. et al (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201: 1205–1215.
42. Rubin D.T. Lo Savio A. Yadron N. Huo D. Hanauer S.B. (2006) Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4: 1346–1350.
43. Safdi M. de Micco M. Sninsky C. Banks P. Wruble L. Deren J. et al (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92: 1867–1871.
44. Sandborn W.J. Kamm M.A. Lichtenstein G.R. Lyne A. Butler T. Joseph R.E. (2007) MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26: 205–215.
45. Sandborn W.J. Korzenik J. Lashner B. Leighton J.A. Mahadevan U. Marion J.F. et al (2010) Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 138 (4): 1286–1296. 1296.e1281–1283.
46. Siegel C.A. (2009) Accidentally ASCENDing into comparative effective research for inflammatory bowel disease. Gastroenterology 137: 1880–1882.
47. Singleton J.W. Hanauer S.B. Gitnick G.L. Peppercorn M.A. Robinson M.G. Wruble L.D. et al (1993) Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 104: 1293–1301.
48. Sutherland L. MacDonald J.K. (2003) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3: CD000543–CD000543.
49. Sutherland L. MacDonald J. (2006) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Collaboration 2: 1–37.
50. Sutherland L.R. May G.R. Shaffer E.A. (1993) Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 118: 540–549.
51. Sutherland L. Roth D. Beck P. May G. Makiyama K. (2002) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 4: CD000544–CD000544.
52. Travis S.P. Stange E.F. Lemann M. Oresland T. Chowers Y. Forbes A. et al (2006) European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55(Suppl. 1): i16–i35.
53. Truelove S.C. (1988) Evolution of olsalazine. Scand J Gastroenterol Suppl 148: 3–6.
54. van Staa T.P. Card T. Logan R.F. Leufkens H.G. (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54: 1573–1578.
55. Velayos F.S. Terdiman J.P. Walsh J.M. (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterology 100: 1345–1353.
56. Zhou S.Y. Fleisher D. Pao L.H. Li C. Winward B. Zimmermann E.M. (1999) Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 27: 479–485.